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Abstract
It is universally acknowledged that genetic diversity is a hallmark of HIV-1 infection, and it is one of the traits that has considerably
hampered the development of an effective vaccine. In a study of full-length HIV-1 genomic sequences (9 kb), we show unique evidence
for complete absence of viral evolution in an individual with truly nonprogressive infection. Gross gene defects were not detected, but the
state of replication incompetence was attributed to the presence of stop codons in the structural genes gag p17 and p24 and in pol RT, which
emerged as a consequence of G–A hypermutation. These inactivating mutations may have occurred early, soon after infection, during the
clonal stage of primary viral replication, since these are the sole archival strains present today. This genetic homogeneity, with 1%
variation between strains over an 8-year period, suggests that only limited proviral integration events occurred in this patient. Further study
on the antigenic properties of this strain may assist in the development of HIV vaccines and therapeutics.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The rate of disease progression from initial infection
until the development of severe immunosuppression varies
greatly among infected individuals. Nonprogressors are dif-
ferentiated from patients with progressive disease by main-
tenance of low or undetectable viral loads and stable CD4
and CD8 T-cell counts (Buchbinder et al., 1994; Cao et
al., 1995; Sheppard et al., 1993). Although many HIV-
infected individuals can survive for more than a decade,
most of these long-term survivors (LTS) eventually
progress to AIDS. There is a small fraction, termed “true”
long-term nonprogressors (LTNP), who do not progress
(constituting 0.8% of the total HIV-positive population),
and represent the extreme end of the clinically asymptom-
atic population (Lefrere et al., 1997). These HIV-infected
individuals maintain stable T cell counts, undetectable
plasma RNA (50 copies/ml) and proviral DNA (10
copies/106 PBMC), and strong antiviral immune responses,
in the absence of antiretroviral therapy, into their second or
third decades of infection. Although many host and viral
factors have been implicated in nonprogression (reviewed in
Saksena et al., 2001), there is no single factor that univer-
sally determines a nonprogressive outcome.
Genetic diversity remains the hallmark of HIV disease
progression. Both LTS and LTNP show similarities in terms
of viral genetic diversity, immune responses, T-cell counts,
and plasma viral loads during the asymptomatic stage (Cao
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et al., 1995; Pantaleo et al., 1995; Wang et al., 2000).
Irrespective of the stage of disease, viral replication continues
and genetic diversity increases (Shankarappa et al., 1998). Host
immune selective pressure has a significant influence on viral
evolution, resulting in the emergence of variants (quasispe-
cies), particularly CTL escape mutants, which increase in dom-
inance as disease progresses (Goulder et al., 1997b; Kelleher et
al., 2001; Shankarappa et al., 1999). Rapid disease progression
and late-stage disease are associated with restricted quasispe-
cies diversity (Halapi et al., 1997; Shankarappa et al., 1998;
Wang et al., 1997, 2000), and accumulation of genetic diver-
sity indicates immunocompetence of the host (Borrow et al.,
1997; Goulder et al., 1997a; Wang et al., 2000; Wolinsky et al.,
1996). However, ongoing viral evolution in asymptomatic in-
dividuals eventually leads to immune escape, or increased
pathogenicity, to the point that disease progression occurs
(Shankarappa et al., 1999). Why this does not occur in a few
rare LTNP needs to be resolved, as this may contribute to new
therapeutic interventions aimed at slowing disease progression.
Truly nonprogressive HIV-infected individuals have
generated enormous interest in the study of mechanisms that
may confer natural control of HIV. To gain a better under-
standing of viral factors that may be associated with true
nonprogression, we performed a detailed molecular inves-
tigation of full-length (9000 bp) HIV-1 strains derived
from a rare, truly nonprogressive individual.
Results
Clinical profile of the study subject
The clinical history of the study subject has been described
in detail elsewhere (Wang et al., 2002). In brief, CD4 counts
were within normal limits, while CD8 counts were elevated.
Plasma viral RNA was undetectable (50 copies) since the
first available specimen, until the present (1993–2002), and
proviral DNA burden was low (10 copies/106 PBMC).
Viral isolation negativity
Isolation of the study subject’s viral strain was attempted
from each sample collected between 1998 and 2001, in
28-day co-cultures. All PBMC and CD8-depleted co-cul-
tures were negative for virus isolation (data not shown).
Increasing input cell number or length of culture did not
facilitate isolation. No evidence of replicating virus was
found in this individual. Viral isolation on PBMC stored
between 1993 and 1998 was not attempted due to insuffi-
cient quantities of cells available.
Detection of antibodies to HIV proteins
Antibodies against all HIV proteins were detected from
serum obtained between 1998 and 2001 (Fig. 1). Western
blot patterns were consistently strongly reactive (4)
against all HIV-1 proteins (gp160, gp120, gp41, p55, p53,
p31, p17 and p24), confirming that the study subject was
infected and exposed to replicating virus.
PCR amplification
Attempts to amplify HIV-1 genome from plasma samples
available between 1998 and 2001 failed, which was consistent
with undetectable plasma viral RNA. Therefore, PBMC were
used for HIV-1 gene amplification, despite the fact that the
proviral DNA burden was 10 copies/106 PBMC. Initially,
only limited gene regions (env, LTR, vpr, nef, and pol) were
successfully amplified using conventional double- and triple-
nested PCR, for phylogenetic analysis. Further, using primer
pairs UP1A and LOW2 targeting the 5 LTR and 3 LTR
regions, respectively, near full-length genomes were success-
fully amplified from PBMC samples collected between 1999
and 2001. In each case, the end 600 bp in the LTR was
amplified separately to complete the full-length genome. Near
full-length genomes were then used as templates for single-
round amplification of individual viral genes, using gene-spe-
cific primer pairs (not shown). All attempts to amplify full-
length genomes from samples collected before 1998 failed,
possibly due to age or DNA degradation of these frozen spec-
imens. High-grade genomic DNA is needed for long-range
PCR. Only isolated genomic segments from env, pol RT, vpr
and nef could be amplified from these older specimens, requir-
ing double-nested PCR for pol and vpr regions, and triple-
nested PCR for env and nef.
Full length HIV-1 genome analysis: gene-by-gene
sequence and phylogenetic comparisons
Multiple full-length HIV-1 genomes from the study sub-
ject were sequenced to determine the level of viral evolu-
Fig. 1. Western blot reactivity of plasma collected between 1998 and 2001,
compared with 1 (a HIV-negative control) and 2 (a HIV-1-positive
control). Antibody binding to all of the major HIV-1 proteins (gp160,
gp120, p31, p55, p17, p24) was observed in the study subject.
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tion, and whether viral gene defects could explain the lack
of disease progression in this individual.
Tight sequence homology was observed in the gene
segments that were studied. The maximum nucleotide vari-
ation (which includes both synonymous and nonsynony-
mous changes) in sequences derived from PBMC samples
collected between 1999 and 2001 was 0.98%, seen in the tat
gene (one nonsynonymous base change, which changed one
of 102 amino acid residues), while there was no nucleotide
variation seen in the vpr, vpu, and nef genes (Table 1). The
maximum nonsynonymous variation seen in gag and pol
was 0.41–0.42% (Table 1), yielding only 1% nonsynony-
mous variation detected in 3 years. Overall, 1% nucleo-
tide variation was detected over 3 years, resulting in 0.49%
non synonymous variation. Since HIV genomes have been
reported to evolve in vivo at a rate of 1% per year and the
env hypervariable regions at 1% (Lukashov et al., 1995),
this genetic diversity over 3 years is negligible.
The HIV-1 amino acid sequences derived from the nu-
cleotide sequences from the study subject were compared
with the prototypic strain HIV-1 NL4.3. Although no major
deletions were observed, a consistent feature was the pres-
ence of stop codons in Gag p17 and p24, and Pol RT (Fig.
2A and C). In addition, the start codon (ATG-methio-
nine-M) in p17 was changed to ATA (isoleucine-I) (Fig.
2A). These gag gene stop codons were further verified by
sequencing multiple clones from proviral genomes over
time (Fig. 2B). The stop codons were a consequence of G–A
hypermutation, characterized by a change of G bases to A in
a particular genomic region (Fig. 2D), which usually occur
in a string-like fashion. The majority of these G–A changes
converted tryptophan (W) residues to stop codons in gag,
but only one in pol (Figs. 2A and C).
Further confirmation of a complete lack of sequence
evolution is based on the highly variable envelope gene,
which was devoid of any changes over time (Fig. 2E). All
hypervariable domains in the env gene (V1–V5) showed
identical peptide sequences. In addition, the C2–V5 region
sequences (650 bp) between 1993 and 2001 were identical
to the respective areas of the full-length sequences (Figs. 2E
and 3K). The absence of evolution was further confirmed by
cloning the vpr gene from samples obtained between 1993
and 2001, which yielded identical sequences over these 8
years (data not shown).
Tight conservation in all functional motifs in accessory
(Figs. 2F–I) and regulatory (Fig. 2J and K) genes was seen
in all full-length genomes, including all cysteine residues in
the Vif protein, which are necessary for viral infectivity (Ma
et al., 1994). Overall, there were no defects, deletions, or
stop codons in these nonstructural genes, with the exception
of a deletion at residue 67 in Vpu. Residue 67 in Vpu is in
the critical cytoplasmic -helical domain II (Fig. 2H). A
detailed search using the HIV Molecular Database showed
the variable nature of this residue between all known HIV-1
subtypes and SIVcpz, but in no sequence was deletion of
this residue was seen. The biological significance of these
deletions is not known. Sequence analysis of the 5 non-
coding LTR also showed complete identity of samples be-
tween 1999 and 2001, with a tight conservation of all
functional motifs (Fig. 2L).
Phylogenetic analysis based on individual gene-by-gene
comparisons also confirmed a lack of viral evolution (Fig.
3A–I). Analysis of partial genomic regions derived from sam-
ples obtained between 1993 and 2001 revealed that pol, env,
nef, and vpr gene sequences were identical (data not shown),
with strong phylogenetic clustering over time (Fig. 3J– M).
This confirmed a complete lack of viral genetic diversity in
vivo over 8 years. Of interest was the phylogenetic tree recon-
structed from the env C2–V5 hypervariable region sequences,
which showed tight clustering (Fig. 3K). Similarly, sequencing
of 15 vpr clones from 1993 to 2001 (Fig. 3M) further con-
firmed a complete lack of viral quasispecies evolution consis-
tent with the presence of a single lineage of HIV-1 in vivo.
Phylogenetic analysis based on the full-length genomes also
confirmed the authenticity of sequences originating from the
study subject, evident from 100% bootstrap estimations for all
three sequences between 1999 and 2001 (Fig. 3N). The tight
clustering of these full-length genomes further supports an
absence of evolution in this unique individual. Thus, it appears
that viral replication in this individual has not occurred since at
least 1993.
Discussion
Truly nonprogressing HIV-infected individuals, who
constitute 0.8% of the total HIV-infected population, are
a subject of intense investigation. These nonprogressors can
provide valuable insight for the development of therapeutics
for natural control of HIV. In this study, we have investi-
gated the molecular structure of full-length HIV-1 genomes
(9 kb) from a rare nonprogressive individual, who, despite
being infected for 14 years, satisfies all of the aforemen-
tioned criteria for a “true nonprogressor.” Based on this
detailed molecular analysis, we show that genomic defects
Table 1
Genetic distances (nucleotide and peptide) between different genomic
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Fig. 2. Alignment of full-length gag amino acid sequences (499 residues) derived from full-length HIV-1 genomes from PBMC, by direct sequencing, showing the
extent of gross defects in the gag gene. The tryptophan (W) codon TGG was changed throughout the gag p17 and p24 genomic regions to the stop codon TAG,
due to high G–A hypermutation, in positions 16, 56, 213, 250, 266, and 317. The start codon ATG was absent in the p17 gene, with methionine substituted for
isoleucine. Boxed areas with asterisks denote stop codons. Other boxed regions represent functional motifs/regions within Gag, as indicated. (b) Alignment of gag
gene clones confirming the presence of stop codons in both p17 and p24 regions. (c) Alignment of full-length pol amino acid sequences (947 residues) derived from
PBMCs, by direct sequencing. Boxed areas with asterisks denote stop codons. Other boxed regions represent functional motifs/regions within Pol, as indicated. (d)
Frequency of G–A hypermutation in the gag gene derived from full-length HIV-1 sequences. GG-to-AG hypermutations are indicated in red, GA-to-AA in cyan,
GC-to-AC. In green, and GT-to-AT in magenta. Black represents no change, while yellow represents gaps. There were 34 G-to-A hypermutations detected
in gag. This phenomenon was identical in all three genomes from 1999, 2000, and 2001. (e) Alignment of full-length envelope amino acid sequences (849
residues). Deletions are denoted by dashes. Boxed areas represent the V1–V5 hypervariable regions, as indicated. (f–i) Alignment of amino acid sequences
derived from Vif (f), Vpr (g), Vpu (h), and Nef (i), sequenced from full-length HIV-1 genomes. Highlighted areas in Vif (f) represent conserved cysteine
residues. Functional domains (boxed regions) are indicated for Vpr (g); for Vpu (h), which represent the N-terminal and cytoplasmic tails; and for Nef (i).
(j–l) Peptide alignment of Tat (j), Rev (k), and non-coding LTR (l) region derived from full-length HIV-1 genomes. Functional domains are highlighted.
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may have rendered the single infecting strain replication
incompetent, hence inducing a state of permanent nonpro-
gression in this unique individual.
The accumulation of genetic diversity seen in slow pro-
gressors and LTNP over time has been associated with host
immune selective pressure, but this nonprogressor had no
Fig. 2 (continued)
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Fig. 2 (continued)
trace of viral evolution, despite potent antiviral immune
responses (Wang et al., 2002). In contrast, lower variability
or homogeneity in viral strains has been correlated with
rapid progression to AIDS (Halapi et al., 1997; Shankarappa
et al., 1998; Wang et al., 1997, 2000). Considerable genetic
variation occurs in the env gene. Given the importance of
env in neutralization, immune escape, viral pathogenesis,
cell tropism, and viral fusion function (Fouchier et al., 1992;
Hwang et al., 1991; Oka et al., 1994; Shioda et al., 1992),
the marked variation seen in env of HIV-1 strains from
individuals with different stages of HIV disease (Kuiken et
al., 1992) is a biologically significant phenomenon. More
importantly, this confirms that viral evolution is an integral
part of HIV pathogenesis, and leads to disease progression.
Therefore, the absence of genetic variability and evolution
in HIV-1 strains from this immunocompetent nonprogressor
is unique, and appears to be a barrier against disease pro-
gression.
From the study subject, a novel and unique nonevolving
HIV-1 strain has been characterized, from uncultured
PBMC, represented as an archival inactive genome. We
were unable to amplify any viral sequences from plasma,
consistent with his persistently undetectable plasma vire-
mia, and the failure to isolate any virus by co-culture sug-
gests that replication-competent genomes no longer exist in
circulation. Intriguingly, this would also suggest that the
mutant genomes arose very soon after infection, and have
been propagated only by cell division. Alternatively, potent
HIV-specific immune responses (Wang et al., 2002) may
have cleared cells infected with the original infecting strain,
leaving only the defective genome in resting cells, which are
silent to antiviral CTL. A longitudinal comparison of vari-
ous genomic segments in pol, env, nef, and vpr clearly
revealed a complete lack of viral evolution, with strains
retaining identical sequences over an 8-year period (1993–
2001), at both the nucleotide and peptide levels. Cloning
analysis further validated the absence of evolution. Further,
to prove this lack of viral evolution, full-length viral ge-
nomes (9000 bp) amplified and sequenced from uncul-
tured PBMC obtained in 1999, 2000, and 2001 revealed
identical sequences at the peptide level with maximum
variation of 0.98%. This was in complete concordance
Fig. 2 (continued)
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with sequences we obtained from small genomic segments
throughout the whole 8-year period. This also suggests an
early eradication of all infectious genomes, probably at the
initial stages of infection, during the clonal expansion stage
of viral replication, after antigenic exposure was sufficient
to induce the development of a full Western blot pattern. In
addition, these data provide evidence for limited integration
events of proviral DNA in this individual.
The lack of sequence evolution demonstrated in the
study subject has not been described before. Convention-
ally, the HIV-1 genome undergoes mutation rates of 1% or
more per year (Lukashov et al., 1995). Thus, genomic vari-
ability of 1% over 8 years based on the entire genome
(especially in the env hypervariable regions), and partial
gene segments between 1993 and 2001, is a unique biolog-
ical and molecular phenomenon. In addition, we could not
rule out errors in Taq polymerase being responsible for
some of these apparent sequence changes. The underlying
reasons for this lack of variability may be a consequence of
defects, primarily stop codons that we observed in p17 and
p24 regions of gag, and the RT region of pol, which may
have eliminated replicative potential of this strain. These
stop codons were created via systematic elimination of
tryptophan residues (W) by a process of “G-to-A hypermu-
Fig. 2 (continued)
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tation” (Pathak and Temin, 1990a,b) in which G-to-A tran-
sitions far exceed all other mutations in viral sequences
(Borman et al., 1995). G-to-A hypermutation was recently
described to be existing in 38% of asymptomatic individuals
and 50% of seroconverters (Janini et al., 2001). However,
the functional relevance between G-to-A hypermutation and
the clinical stage of disease remains poorly understood.
Further, it is unclear whether hypermutation is influenced
by viral escape or if it is a function of the cell population
harboring the virus. The loss of coding potential of these
hypermutated HIV sequences strongly suggests that they are
incapable of generating progeny virions and cannot contrib-
ute to the HIV gene pool (Janini et al., 2001). In the case of
the study subject, the extent of G-to-A hypermutation was
significantly higher in gag and pol genes, in which we
observed stop codons. PBMC-derived sequences may dis-
play a higher incidence of G–A hypermutation (Janini et al.,
2001). However, our recent longitudinal analysis of full-
length HIV-1 genomes from an American cohort of 20 slow
progressors and nonprogressors (Wang et al., 2000, and
unpublished data) did not show a predominance of G–A
hypermutation in the nonprogressors, thereby suggesting a
minimal role of this phenomenon in defining the rate of
disease progression. Whether G–A hypermutation is a tran-
sitory phenomenon or is permanent remains unclear. It was
suggested that G–A hypermutation detected after culture
may be a transitory phenomenon, and can be induced by
mitogens (Janini et al., 2001). Thus, based on the uniform
presence of a strain bearing G–A hypermutation in the study
subject, we hypothesize that G–A hypermutation may play
a significant role in rendering HIV genomes defective, and
may be important in containing HIV disease progression in
some cases.
The persistence of defects in the genome throughout the
study period suggests that no new integrants were generated
during this period. Together, the absence of plasma viremia
and viral evolution and the presence of strong anti-HIV
immune responses (Wang et al., 2002) may have contrib-
uted to truly nonprogressive HIV disease in this individual.
Based on broad potent immune responses against multiple
Gag antigens, cells expressing intact antigens may have
been eradicated long ago, leaving only cells containing
defective HIV genomes, being replicated only by normal
cell mitotic processes, not by viral replication.
Based on the prevalence of stop codons in HIV-1 ge-
nomes amplified from the study subject over 8 years, it is
unlikely that the synthesis of normal p17, p24, and Pol RT
proteins is occurring in vivo. The p17 matrix protein is
critical in the transport of the pre-integration complex to the
host cell nucleus (Bukrinsky et al., 1992), the p24 core
protein for viral maturation, budding, and viral infectivity,
and RT for integration of the provirus into the genome.
Therefore, stop codons in these genes would interfere with
expression of functional proteins, which would render the
virus both infection and replication incompetent. Of partic-
ular interest is the recognition of antibodies to p17 and p24
by Western blot. Sustained antibody responses to an appar-
ently defective HIV-1 protein have also been observed in
studies of a New York patient (Binley et al., 1998). Simi-
larly, the detection of antibody responses to both p17 and
p24 proteins by Western blot from samples taken from the
study subject between 1998 and 2001 does not imply that
Fig. 2 (continued)
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these proteins are currently being produced. Binley et al.
proposed a number of hypotheses to explain how antibody
responses could persist in the absence of apparent viral
replication, including presentation of remnant virus on fo-
licular dendritic cells; long-lived memory and persistence of
antibody-secreting B cells; and presence of intact virions
replicating within some privileged site that is not in rapid
equilibrium with blood. While we have not been able to
obtain lymph node or bone marrow biopsies from the study
subject primarily due to the patient’s personal decision, our
comprehensive study of the immunobiological mechanisms
operating in the study subject (Wang et al., 2002) proposed
different reasons for the persistence of a broader T- and
B-cell antiviral memory. One speculative possibility is that
the defective genomes are harbored by a population of
activated T cells, perhaps HIV-specific CD4 T cells, that
may be producing defective viral antigen. This also pro-
vides a mechanism for the clonal nature of this strain’s
DNA replication, without retroviral reinfection and muta-
tion. This scenario is the subject of ongoing studies.
This is the first demonstration of a complete absence of
HIV-1 evolution and replication in a human, along with
evidence of gene defects that may have induced replication
incompetence of the study subject’s viral strain. The per-
sistence of gene defects over 8 years demonstrates that
genetic repair of these regions does not occur. This is starkly
different from the PBMC-derived HIV-1 strains from the
Sydney Blood Bank Cohort members, in which the virus
underwent slow but continual change, leading to resumption
of pathogenic potential and eventually to disease progres-
sion in two individuals (Deacon et al., 1995; Learmont et
al., 1999). The strain described in this study, which may be
able to induce a protective immune response due to some
antigen production, while the ability to replicate and evolve
is ablated by the gross gene defects, could prove to be an
ideal candidate for a DNA-based HIV vaccine. Further
biological studies of cloned versions of this defective pro-
virus are needed to confirm protein expression in vitro.
Materials and methods
Study subject
A 53-year-old man, presumed infected in December
1988, from a partner who died of AIDS in 1992, was
diagnosed HIV-positive in 1992. He has remained asymp-
tomatic after up to 14 years of infection. While he has not
received combination antiretroviral therapy, he has partici-
pated in numerous therapeutic interventions. These and
other clinical details have been reported (Wang et al., 2002).
Viral load measurements
HIV-1 plasma RNA load was determined using the Am-
plicor HIV-1 Monitor “ultrasensitive” Version 1.5 (Roche
Diagnostics Systems, Branchburg, NJ, USA), according to
the manufacturer’s protocol.
PBMC isolation and genomic DNA extraction
Fresh EDTA blood was centrifuged at 1800 rpm for 10
min to separate plasma, and PBMC were fractionated from
the remaining blood cells by Ficoll–Hypaque gradient cen-
trifugation. Genomic DNA was extracted from 5  106
PBMC using the QIAmp Blood kit (Qiagen, GmBh, Ger-
many) according to the manufacturer’s protocol.
Virus isolation
PBMC 1  107 were co-cultured in RPMI 1640  10%
FCS and 10% IL-2 (IL-2 medium) with an equal number of
phytohemagglutinin (PHA)-stimulated uninfected donor
PBMC. Viral isolation in the study subject was also at-
tempted using 5  107 CD8-depleted PBMC (using CD8
Dynal beads, according to the manufacturer’s protocol).
Cultures were maintained twice weekly by addition of fresh
PHA-stimulated HIV-negative donor PBMC and IL-2 me-
dium, for a period of 4 weeks. Viral replication was mea-
sured by assaying p24 antigen in culture supernatants ac-
cording to the manufacturer’s protocol (Beckman Coulter,
USA).
Polymerase chain reaction
Amplification of proviral DNA was conducted using an
external and internal PCR. For external reaction, 5 l of
10 buffer, 5 l of MgCl2 (25 mM), 0.8 l (100 mM) of
dNTP, and 1 l (20 pmol) of oligonucleotide primers (ex-
ternal) 1 and 2 were mixed together with 0.5 l (2.5 U) of
Taq DNA polymerase and 10 l (equivalent to 1 g) DNA
template. The PCR was run for 35 cycles (94°C for 30 s,
55°C for 1 min, and 72°C for 2 min), after an initial 94°C
for 5 min before the first cycle. The internal reaction con-
ditions were identical to those of the first PCR round, but
Fig. 3. Neighbor joining phylogenetic reconstructions based on complete nucleotide sequences for gag (A), envgp160 (B), pol (C), rev (D), tat (E), vif (F),
vpu (G), nef (H), and vpr (I), amplified from the full-length genomes, from the PBMCs, obtained between 1999 and 2001. Figures J, K, L, and M show the
comparison of small genomic segments amplified from proviral DNA from 1993-2001 against the segments amplified from the full-length HIV-1 genomes
in the pol (J), env (K), nef (L), and vpr (M) regions over time. Multiple clones of vpr (M) were created to assess diversity in vivo. Phylogenetic tree (N) based
on full-length nucleotide sequences (9000 bp). Other non-B subtypes (retrieved from Los Alamos Database, Kuiken et al., 2001) used for comparison
clustered away from the study subject’s viral strain.
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only 25 cycles. PCR products were subsequently run on a
1.5% agarose gel.
RNA extraction from plasma and reverse transcription PCR
Viral RNA from plasma was extracted using Tri-Reagent
(Sigma, St. Louis, MO, USA) and cDNA synthesis was
conducted using the Reverse Transcriptase System (Pro-
mega, Madison, WI, USA) with a total of 2 g RNA in a
final volume of 20 l. The reaction mixture contained 10
reaction buffer, 2 l dNTP mix (10 mM), 40 units (U) of
RNasein ribonuclease inhibitor, 15 U AMV reverse tran-
scriptase (AMV-RT, a high-fidelity enzyme), and 0.5 g
oligo(dT); the remaining volume was made up to 20 l
using nuclease-free water. The reaction mixture was then
incubated at 42°C for 30 min and heated at 99°C for a
further 5 min. Conditions for the amplification of cDNA
were identical to those used for regular PCR as mentioned
in the previous section.
Amplification of full-length HIV-1 genomes
The GeneAmp XL PCR kit (Perkin-Elmer, Emeryville,
CA, USA) was used to amplify near full-length HIV genomes
involving a two-layered PCR. Two primers were used for the
amplification of full-length genomes from low copy numbers:
UP1A (5-AGTGGCGCCCGAACAGG-3), directed at the 5
LTR, and LOW2 (5-TGAGGCTTAAGCAGTGGGTTTC-
3), directed near the end of nef to capture the 3 LTR. To
minimize PCR mispriming and primer oligomerization in the
internal reaction, a hot start technique was applied using the
lower reagent. After allowing the wax to harden into a solid
separating layer, the upper layer comprising 18 l of 3.3 XL
buffer, mixed with 2 l of rTh DNA polymerase (XL), was
added. One microgram of DNA template, in addition to PCR
water to make a final volume of 60 l, was added. Following
addition of the upper layer to the sample tube of wax the
mixture was heated at 94°C for 1 min followed by 94°C for
15 s, 68°C for 10 min, running for 25 cycles. An extra 12
cycles were added using 94°C for 15 s, 68°C for 10 min, and
an increment of 15 s Ten to fifteen microliters per cycle. of
amplified product was used for gel electrophoresis. Near full-
length genomes were then used as a template for the amplifi-
cation of individual genes. Before sequencing, all PCR prod-
ucts were purified using the Millipore multiscreen manifold
system according to the manufacturer’s protocol. Sequencing
reactions were carried out using dye terminators (Version 3
Big Dye Kit, Perkin Elmer), and were purified on Sephadex 50
using the Millipore multiscreen manifold system.
Ligation of PCR products and transformation and
screening of positive clones
Purified PCR fragments were ligated with the PGEM-T
vector system (Promega), and ligated products were used in
transforming competent JM109 Escherichia coli cells, pro-
vided with the kit, according to the manufacturer’s protocol.
One hundred microliters of the resuspended cells in SOC
medium were gently spread on X-Gal (40 l of 40 mg/ml)
IPTG (20 l of 200mg/ml) and ampicillin (100 l of 100
mg/ml) plates. Plates were incubated at 37°C overnight.
White clones were handpicked, and resuspended in 30 l
sterile PCR water. Sample tubes were heated at 93–95°C for
10 min to lyse the cells, followed by centrifugation at
14,000 for 5 min. Three microliters of supernatant was used
to amplify the desired viral genomic region(s) to verify
positive clones, which were then cultured in 2 ml Luria
broth at 37°C overnight. Plasmid DNA was extracted as
previously described (Wang et al., 1996) and purified plas-
mid preparations (as described above) were used for se-
quencing.
Sequence and phylogenetic analysis
Sequence obtained from the study subjects were first
BLAST searched and also compared against all lab-derived
HIV-1 sequences to rule out any possibility of contamina-
tion. Multiple nucleotide and peptide sequence alignments
were generated using CLUSTAL W v1.7 (Thompson et al.,
1994), from the GCG package, with default settings, and
improved manually. The pairwise nucleotide distance was
calculated using the Kimura two-parameter model in
PHYLIP. Phylogenetic reconstructions were performed
with the neighbor-joining method, also using the Kimura
two-parameter distance matrix, with a transition to trans-
version ratio of 2. Analysis was performed with DNADIST
and NEIGHBOR, part of the PHYLIP program. One hun-
dred bootstrap replications were applied to generate phylo-
genetically significant temporal relationships, using Seq-
boot. G–A hypermutation was anlyzed using Hypermut,




Serum or plasma samples were heat inactivated at 56°C
for 30 min. Reactivity to HIV-1 Env, Gag, and Pol proteins
was confirmed using the Genelabs Diagnostic HIV Blot 2.2
Kit (Genelabs Diagnostic, Singapore) as per the manufac-
turer’s instructions. Appropriate controls (internal sample
control IgG to minimize false negatives and HIV-1-positive
control) provided with the kit were run. The Western blot
was considered positive for antibody to HIV if bands cor-
responding to gp160, 120, or 41 were present in combina-
tion with p66, p51, p31, and p24, or p55 and p17.
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